The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000481370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/04/2026
Date registered
Help: Date registered
17/04/2026
Date last updated
Help: Date last updated
10/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Food Effect Open-Label, Randomized Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OV4071 in Healthy Male and Female Participants.
Scientific title
A Food Effect Open-Label, Randomised Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OV4071 in Healthy Male and Female Participants.
Additional trial identifiers [1] 316987 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records
This study is a related food effect cohort (Part B) within a multi-part Phase 1 clinical development program for OV4071. The associated single and multiple ascending dose study (Parts A and C) is registered separately under ACTRN12626000480381.

Health condition
Health condition(s) studied:
Parkinson's Disease 341446 0
Condition category
Condition code
Neurological 337509 337509 0 0
Parkinson's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The study will be a Phase 1, single-centre, randomized, open-label food effect inpatient study of the safety and tolerability of a single dose of oral OV4071 in healthy male and female participants.
Part B is a single ascending dose (SAD) dose administered orally with food assessing the food effect in a cohort of 8 participants. The dose for Part B will be determined by the Data Review Committee (DRC) and will not be lower than 10 mg or exceed a maximum dose of up to 800 mg. All doses are administered in-clinic under direct supervision of trained study staff members and mouth checks are performed after each administration to confirm capsule ingestion. This information is documented in the study source documents.
The study sponsor, the study principal investigator (PI), medical monitor, and a pharmacokineticist will review data summaries from the food effect cohort and recommend whether to proceed with multiple ascending dose (MAD) cohort dosing.
The food effect cohort will assess the safety profile of oral OV4071 on electrocardiogram (ECG) parameters, vital signs, physical and neurological examinations, hematology and chemistry laboratory results and adverse events (AEs). In addition, neurophysiologic pharmacodynamics (PD) variables in the study are qualitative ECG, particularly the timing and extent of ECG changes in relation to the doses administered.
Part B is a single cohort of 8 participants who will be randomised to a fasted and fed group (fasted 4: fed 4). The participants will receive a single dose of OV4071 and monitored for 2 days for the in-patient portion (Day 3) followed by a 7 day washout period. On Day 8 the participants return to the unit in a cross over design where those initially administered a single dose under fasted conditions will receive a single dose under fed conditions and vice versa, those that received the single dose under fed conditions will receive the single dose under fasted conditions and monitored for 2 days for the in-patient cross over portion (Day 3).
Participants will be fasted for 8 hours, with nil by mouth before dosing, take the pill with a glass of water, and continue to fast for 4 hours post dosing.
The meals administered during part B will consist of a standard high-fat breakfast of 2 eggs fried in butter, 80 g of bacon, 40 g of toast, 25 g of butter, 120 g of potatoes and 240 ml of whole milk (i.e. 180 kcal proteins, 220 kcal carbohydrates, and 600 kcal fat). Dosing is completed within 5 minutes of the meal being eaten.
Monitoring visits by the Clinical Research Organisation (CRO) to the study site will be made periodically during the study to ensure all aspects of the protocol are followed.
Intervention code [1] 333731 0
Treatment: Drugs
Description of the comparator or control
Participants are their own controlled, with a single dose of OV4071 administered under fasted conditions and fed conditions.
Control group
Active

Outcomes
Primary outcome [1] 345026 0
To assess the safety and tolerability of a single dose of oral OV4071 under fasted and fed conditions in healthy male and female participants. This will be assessed as a composite outcome.
Timepoint [1] 345026 0
Vital signs (blood pressure and heart rate): screening, baseline, D1-3, D8-D10, and D15 pose-dose. 12 lead ECGs: screening, baseline, D1-D3, D8-D10, and D15 post-dose. Hematology, Coagulation, Chemistry and urine Analysis: screening, baseline, D1-D3, D8-D10, and D15 post-dose. C-SSRS at screening, baseline, D7,D10, and D15 post-dose.
Secondary outcome [1] 460214 0
To characterise the Pharmacokinetics (PK) of OV4071 in healthy male and female participants under fasted and fed conditions.
Timepoint [1] 460214 0
Blood PK: timepoints to be collected on D1 at pre-dose then 30 mins, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose. D8 at pre-dose then 30mins, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours post-dose.

Eligibility
Key inclusion criteria
1. Participants must give written informed consent prior to participation in the study. 2. Participant agrees not to post any of the participant's personal or medical data or information related to the study on any website, message board(s), online groups, or social media website (e.g. Facebook, Instagram, X etc) until notified that the study is completed. 3. Participant must be willing and able to comply with the study procedures (including diet) and visit schedules and must be able to follow verbal and written instructions. 4. Male and female participants aged 18 to 55 years (inclusive) at the time of informed consent. 5. Weighs at least 50 kgs and body mass index (BMI) greater than or equal to 18.0 and les than 35.0 kg/m2 9inclusive) at screening. 6. Continuous non-smoker who has not used nicotine containing products 9including vaping) for at least 1 month prior to the first dosing and throughout the study, based on participant self-reporting. 7. Resting semi-supine systolic blood pressure 90 to 145 mmHg (inclusive) and diastolic blood pressure no higher than 90 mmHg at Screening and Check-in (D-2 or D-1) to be taken after about 10 minutes in semi-supine position. 8. A 12-lead ECG with no clinically significant abnormalities as deemed by the Principal Investigator or delegate and Fredericia corrected QT interval (QTcF) equal to 450 milliseconds in males and 470 milliseconds in females at Screening and Check-in (D-2 or D-1) to be taken after about 10 minutes in semi-supine position. 9. Resting semi-supine pulse rate between 45 and 100 beats per minute at Screening and Check-in (D-2 or D-1). 10. Physical examination and laboratory investigations within the normal reference range, or if outside the reference ranges, deemed not clinically significant in the opinion of the Principal Investigator or delegate. In the event the Principal Investigator or delegate deems grade 2 value at screening to be not clinically significant, the Principal Investigator or delegate will obtain approval for inclusion of participant from medical monitor and Sponsor (Clinical Lead) at Screening. Out-of-range labs (not within reference ranges) at D-2 or D-1) are exclusionary if deemed clinically significant by the Principal Investigator or designee: exception include lab results for Alanine aminotransferase (AST), Aspartate aminotransferase (AST), Gamma glutamyl transferase (GGT), and Alkaline phosphatase (ALP). Creatinine which would be exclusionary at Screening and Check-in (D-2 or D-1) if greater than 1.5x the upper limit of normal 9ULN) or reference ranges regardless of clinical significance. 11. Screening EEG free from abnormalities, including data quality issues, that could confound interpretation of Pharmacodynamic (PD) measures. 12. Willing to abstain from illicit drugs, alcohol and nicotine products/tobacco use during study participation. 12. Participant must be willing to stay within the clinical research unit for the duration of the in-patient study period and return for all additional study visits as specified by the protocol. 14. Female participants who are sexually active with the opposite sex and of childbearing potential (defined as first menarche through post-menopause or permanent sterilisation) must agree to use a highly effective method of birth control from time of screening and for 1 month following the last dose of study drug combined with the use of a condom by the male partner. 15. Female participants not of childbearing potential due to surgical sterilisation (at least six weeks after hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) confirmed by medical history, or menopause. Menopausal women include women with spontaneous amenorrhea for at least 12 months without an alternative medical cause and a follicle-stimulating hormone level greater than 40 IU/L. 16. Male participants (post-pubertal unless permanently sterilised by bilaterial orchidectomy or vasectomy with confirmed azoospermia) must agree to use male contraception (condom) combined with the use of a highly effective method of contraception by the female partner, and/or abstinence from time of screening and for 90 days following the last dose of study drug.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. history or presence of gastritis, gastrointestinal tract disorder, gastric bypass surgery, or hepatic disorder or other clinical condition which, in the opinion of the Principal Investigator or designee, may affect the absorption, distribution, metabolism, or elimination of study drug. History of cholecystectomy and diagnosis of Gilberts syndrome is also exclusionary. 2. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, psychiatric disorder, or loss of consciousness (LOC) due to head injury for longer than 30 minutes (Moderate traumatic Brain Injury) as determined by the Principal Investigator (or designee). 3. Renal clearance defined as an average of less than 60 ml/min using the Cockroft and Gault formula. 4. History or presence of alcohol or drug abuse within the past 2 years prior to screening visit as determined by the Principal Investigator (or designee) and guidance. Drug and alcohol tests will be conducted at Screening and on D-1 and may be repeated during the trial at the discretion of the PI. 5. history or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds. 6. Risk of suicide according to the Principal Investigator's or delegate's clinical judgement (e.g. per C-SSRS) or has made a suicide attempt in the previous year prior to Screening visit. 7. Unable to refrain from or anticipated use of: a. Any (oral and non-oral) systemic drug including prescription (with exception of non-oral highly effective contraception) and nonprescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing and throughout the study, including the follow-up period. After the first dose of study drug, paracetamol/acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the Principal Investigator or designee. b. Alcohol, caffeinated and dietary products such as grapefruit, Seville oranges etc. c. Any product, remedy, supplement, or medication containing cannabidiols (CBD), Tetrahydrocannabinol 9THC) or related compounds within 30 days prior to the first dosing and throughout the study, including the follow-up period. 8. Has been on a diet incompatible with the on-study diet with the phase of the study to which they are enrolled (Part A, B, or C), in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study. 9. Participation in another clinical study within 30 days prior to the first dose. The 30 days window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to D1 of the current study. If the previous investigational product has a long half-life, three months or five half-lives (whichever is longer) should have passed; participation in a clinical trial involving an investigational product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. 10. Receipt of vaccination (inclusive of influenza and SARS COV2) within 14 days of dosing (D1). 11. If male, the participant intends to donate sperm during the course of the study or for 90 days following the last dose of study drug. 12. If female, the participant is pregnant or intending to become pregnant before participating in this study, during the study, and within 1 month after last dose of the study drug; or intending to donate ova during such time period; or lactating. 13. Ovid employees or Investigator site personnel where the study is being conducted and/or their immediate family. Note: immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. 14. Participants who have Obstructive Sleep Apnea or any other conditions that can cause daytime somnolence, including individuals who work night shifts or who are otherwise typically nocturnal. Any other contraindications for the EEG procedures per discretion of the PI. 15. Individuals who, in the opinion of the Investigator or designee should not participate in this study. 16. Taking medications that are CYP2C8 and CYP3A4 strong inhibitors or inducers; or a sensitive substance for P-gp, BCRP or MATE1 and 2-K transporters, especially those with narrow Therapeutic Window.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A randomisation schedule will be provided from the unblinded biostatistician to the unblinded pharmacy staff in a password-protected file, which will be used solely by the unblinded pharmacy staff for treatment assignment. Based on the randomisation schedule, the unblinded pharmacy staff will prepare code-break envelopes containing the treatment assignment information. In the Food Effect cohort the randomisation schedule will indicate which participants will be dosed fasted and which will be dosed under fed conditions.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block. Computerised sequence generation: An unblinded biostatistician will generate the randomisation schedule using a computer-based random number generator, applying permuted block randomisation (block size 8). Participants randomised 4 to 4 (OV4071 single dose under fasted to OV4071 single dose under fed conditions).
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29965 0
CMAX Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 46340 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 28422 0
United States of America
State/province [1] 28422 0
Biotrial New Jersey

Funding & Sponsors
Funding source category [1] 321582 0
Commercial sector/Industry
Name [1] 321582 0
Ovid Therapeutics Australia Pty Ltd
Country [1] 321582 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Ovid Therapeutics Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324382 0
None
Name [1] 324382 0
Address [1] 324382 0
Country [1] 324382 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320111 0
Bellberry Human Research Ethics Committee J
Ethics committee address [1] 320111 0
Ethics committee country [1] 320111 0
Australia
Date submitted for ethics approval [1] 320111 0
28/01/2026
Approval date [1] 320111 0
06/03/2026
Ethics approval number [1] 320111 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149470 0
Dr Michele De Sciscio
Address 149470 0
CMAX Clinical Research Pty Ltd, Level 5 18a North Terrace Adelaide SA 5000
Country 149470 0
Australia
Phone 149470 0
+61 422447902
Fax 149470 0
Email 149470 0
Contact person for public queries
Name 149471 0
Matthew Jung
Address 149471 0
Ovid Therapeutics, 441 9th Avenue, NY, NY 10001
Country 149471 0
United States of America
Phone 149471 0
+1 203 623 1996
Fax 149471 0
Email 149471 0
Contact person for scientific queries
Name 149472 0
Julia Tsai, PhD
Address 149472 0
Ovid Therapeutics, 441 9th Avenue, NY, NY 10001
Country 149472 0
United States of America
Phone 149472 0
+1 203 623 1996
Fax 149472 0
Email 149472 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.